Law360 (November 20, 2020, 6:17 PM EST) -- Two AstraZeneca subsidiaries have escaped a $275M suit lodged by investors in newly acquired biopharmaceutical company Amplimmune, dodging claims that they owed stockholders milestone payments related to the development of two cancer-fighting therapies.
According to the 74-page opinion filed Wednesday in Delaware Chancery Court, Amplimmune investors failed to prove that AstraZeneca drug unit Zeneca Inc. and biopharmaceutical researcher MedImmune LLC had breached an earn-out provision in a merger agreement made when acquiring Amplimmune by failing to make two milestone payments on time while developing anti-cancer therapies.
In order for investors to receive milestone payments, the companies had to achieve "successful completion"...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!